|
US7090843B1
(en)
†
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
AU2002363939A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
WO2003055527A2
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
|
KR100829283B1
(ko)
|
2002-01-09 |
2008-05-13 |
메다렉스, 인코포레이티드 |
Cd30에 대한 인간 모노클로날 항체
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
SI2357006T1
(sl)
*
|
2002-07-31 |
2016-01-29 |
Seattle Genetics, Inc. |
Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
|
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
|
MX2007003533A
(es)
|
2004-10-01 |
2007-05-23 |
Medarex Inc |
Metodos de tratar linfomas cd30 positivas.
|
|
JP2008530244A
(ja)
|
2005-02-18 |
2008-08-07 |
メダレックス, インク. |
フコシル残基を欠くcd30に対するモノクローナル抗体
|
|
CA2625998C
(en)
*
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
WO2008025020A2
(en)
*
|
2006-08-25 |
2008-02-28 |
Seattle Genetics, Inc. |
Cd30 binding agents and uses thereof
|
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
|
EP2641618A3
(de)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
AU2008310908B2
(en)
|
2007-10-12 |
2014-01-09 |
Seagen Inc. |
Combination therapy with antibody-drug conjugates
|
|
CN104650230A
(zh)
|
2008-01-31 |
2015-05-27 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
|
PT2326350E
(pt)
|
2008-09-08 |
2013-12-10 |
Psma Dev Company L L C |
Compostos para matar células cancerosas resistentes a taxano, que expressam psma
|
|
CA2749115C
(en)
|
2009-01-09 |
2022-06-21 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
WO2012054748A2
(en)
|
2010-10-22 |
2012-04-26 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
EP2793949B1
(de)
|
2011-12-23 |
2018-08-22 |
Innate Pharma |
Enzymatische konjugation von antikörpern
|
|
KR101932697B1
(ko)
*
|
2012-04-27 |
2019-03-21 |
노보 노르디스크 에이/에스 |
사람 cd30 리간드 항원 결합 단백질
|
|
EP2872894B1
(de)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening von konjugierten antikörpern
|
|
MX364484B
(es)
|
2012-10-11 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo-fármaco.
|
|
ES2782248T3
(es)
|
2012-10-19 |
2020-09-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
|
|
EP2916872B1
(de)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Kennungen für tgase-vermittelte konjugation
|
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
TWI716339B
(zh)
|
2012-12-21 |
2021-01-21 |
荷蘭商台醫(有限合夥)公司 |
親水性自消耗連接子及彼等之共軛物
|
|
EP2968582B1
(de)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Festphasen-tgase-vermittelte konjugation von antikörpern
|
|
KR20150132864A
(ko)
|
2013-03-15 |
2015-11-26 |
애브비 인코포레이티드 |
항체 약물 접합체(adc) 정제
|
|
US20140286969A1
(en)
|
2013-03-15 |
2014-09-25 |
Abbvie Inc. |
Anti-egfr antibody drug conjugate formulations
|
|
SG11201508358RA
(en)
|
2013-04-09 |
2015-11-27 |
Boston Biomedical Inc |
2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
|
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
CA2914189C
(en)
|
2013-06-21 |
2023-03-14 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
NZ758050A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
|
AU2015210578B2
(en)
|
2014-01-29 |
2020-04-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
|
|
PT3122757T
(pt)
|
2014-02-28 |
2023-11-03 |
Hangzhou Dac Biotech Co Ltd |
Ligantes carregados e as suas utilizações em conjugação
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015276821A1
(en)
|
2014-06-20 |
2017-01-12 |
Abgenomics International Inc. |
Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
|
|
DK3160513T3
(da)
|
2014-06-30 |
2020-04-06 |
Glykos Finland Oy |
Saccharidderivat af en toksisk payload og antistofkonjugater deraf
|
|
EP3193915A1
(de)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
|
|
EP3262071B8
(de)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von anti-cd79b-immunkonjugaten
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
|
US20180140572A1
(en)
|
2015-06-03 |
2018-05-24 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
WO2015151078A2
(en)
|
2015-06-15 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Hydrophilic linkers for conjugation
|
|
CN108449940B
(zh)
|
2015-07-12 |
2021-06-08 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3380620B1
(de)
|
2015-11-23 |
2024-07-03 |
Novartis AG |
Optimierte lentivirale transfervektoren und verwendungen davon
|
|
SG11201805451TA
(en)
|
2015-12-30 |
2018-07-30 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
ES2880731T3
(es)
|
2016-01-08 |
2021-11-25 |
Altrubio Inc |
Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
JP7073266B2
(ja)
|
2016-03-25 |
2022-05-23 |
シージェン インコーポレイテッド |
Peg化薬物リンカー及びその中間体を調製するためのプロセス
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
CN110099682B
(zh)
|
2016-11-14 |
2023-03-31 |
杭州多禧生物科技有限公司 |
偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
EP3538221B1
(de)
|
2016-11-14 |
2024-10-09 |
Takeda Pharmaceutical Company Limited |
Pediatrische menschliche dosierung für anti-cd30 antikörpers-arzneimittel konjugate brentuximab vedotin
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
|
EP4043485A1
(de)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療
|
|
EP3589647A1
(de)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp-inhibitor-zusammensetzungen und verwendungen zur chimären antigenrezeptortherapie
|
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
がんを処置するための方法
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
IL316538A
(en)
|
2017-10-11 |
2024-12-01 |
Seagen Inc |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
KR20200069358A
(ko)
|
2017-10-25 |
2020-06-16 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
EP3700933A1
(de)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
US20220226439A1
(en)
|
2017-11-01 |
2022-07-21 |
Seagen Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
CN117003874A
(zh)
|
2018-03-20 |
2023-11-07 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
|
AU2019240403A1
(en)
|
2018-03-23 |
2020-10-08 |
Seagen Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11584799B2
(en)
|
2018-09-24 |
2023-02-21 |
Medical College Of Wisconsin, Inc. |
Anti-CD30 antibodies and methods for treating CD30+ cancer
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
US20200102399A1
(en)
|
2018-10-01 |
2020-04-02 |
Seattle Genetics, Inc. |
Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
|
|
CA3119467A1
(en)
|
2018-11-20 |
2020-05-28 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
EP3924055B1
(de)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivate und verwendungen davon
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
|
US20220160771A1
(en)
|
2019-04-10 |
2022-05-26 |
Iulia Diaconu |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
BR112022004913A2
(pt)
|
2019-09-18 |
2022-06-07 |
Baili Bio Chengdu Pharmaceutical Co Ltd |
Derivado de camptotecina e conjugado do mesmo
|
|
MX2022003357A
(es)
|
2019-09-25 |
2022-05-03 |
Seagen Inc |
Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
|
|
JP2022550851A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
カンプトテシンペプチドコンジュゲート
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
MX2022005240A
(es)
|
2019-11-04 |
2022-08-19 |
Seagen Inc |
Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
WO2021148003A1
(zh)
|
2020-01-22 |
2021-07-29 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
|
AU2021212193A1
(en)
|
2020-01-31 |
2022-09-08 |
Celgene Corporation |
Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma
|
|
EP4129345A4
(de)
|
2020-03-25 |
2023-11-29 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmazeutische zusammensetzung mit antikörper-wirkstoff-konjugat und verwendung davon
|
|
MX2022011769A
(es)
|
2020-03-25 |
2022-10-18 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Metodo de preparacion de medicamento de conjugado de anticuerpo.
|
|
CN115955980A
(zh)
|
2020-04-10 |
2023-04-11 |
思进公司 |
电荷可变接头
|
|
AU2021273256A1
(en)
|
2020-05-13 |
2022-12-15 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-CD30 antibody-drug conjugates
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202246242A
(zh)
|
2021-01-15 |
2022-12-01 |
美商西健公司 |
免疫調節抗體藥物結合物
|
|
US12036286B2
(en)
|
2021-03-18 |
2024-07-16 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202304514A
(zh)
|
2021-04-20 |
2023-02-01 |
美商思進公司 |
抗體依賴性細胞毒性之調節
|
|
EP4330381A1
(de)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
System zur herstellung von viralen vektoren
|
|
KR20240015670A
(ko)
|
2021-05-28 |
2024-02-05 |
씨젠 인크. |
안트라사이클린 항체 접합체
|
|
MX2024005080A
(es)
|
2021-10-29 |
2024-05-13 |
Seagen Inc |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
CN114891101B
(zh)
*
|
2021-12-02 |
2023-06-16 |
吉林省农业科学院 |
一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
|
|
MX2024011292A
(es)
|
2022-03-17 |
2024-09-27 |
Seagen Inc |
Conjugados de camptotecina.
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CA3252067A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory Antibody-Drug Conjugates
|
|
CN120076829A
(zh)
|
2022-10-18 |
2025-05-30 |
明治制果药业株式会社 |
T细胞肿瘤的治疗剂
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
WO2024197151A2
(en)
|
2023-03-22 |
2024-09-26 |
Salubris Biotherapeutics, Inc. |
Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025090774A1
(en)
|
2023-10-24 |
2025-05-01 |
Seagen Inc. |
Chemotherapeutic compounds and methods of use
|
|
TW202527996A
(zh)
|
2023-10-31 |
2025-07-16 |
美商思進公司 |
使用抗cd30抗體-藥物結合物治療癌症之方法
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025169056A1
(en)
|
2024-02-06 |
2025-08-14 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
CN119331093B
(zh)
*
|
2024-11-04 |
2025-07-11 |
武汉伊莱瑞特生物科技股份有限公司 |
一种抗CD30的兔源Fab抗体及其制备方法和应用
|